The assay was designed to detect all known variants of the virus that causes COVID-19, the company said. It received conditional approval from the New York State Department of Health in late December.
The sample collection kit enables the collection of own nasal swab specimens without supervision by medical personnel. Samples are mailed to Applied DNA Clinical Labs with results available in 24 to 48 hours, the company said.
Shares were down 1.5% in recent trading Friday.
Price: 3.90, Change: -0.01, Percent Change: -0.26
|Needham Adjusts Price Target on Dynatrace to $42 Fro...|
|Mastercard, OPay Enter Into Digital Payment Collabor...|
|Coastal Financial Names Curt Queyrouze as New President|
|-- Earnings Flash (CBAT) CBAK ENERGY TECHNOLOGY Repo...|
|European Natural Gas Prices Rise as EU Member States...|